| Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention Z Younossi, QM Anstee, M Marietti, T Hardy, L Henry, M Eslam, J George, ... Nature reviews Gastroenterology & hepatology 15 (1), 11-20, 2018 | 3730 | 2018 |
| A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement M Eslam, PN Newsome, SK Sarin, QM Anstee, G Targher, ... Journal of hepatology 73 (1), 202-209, 2020 | 2127 | 2020 |
| MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease M Eslam, AJ Sanyal, J George, A Sanyal, B Neuschwander-Tetri, ... Gastroenterology 158 (7), 1999-2014. e1, 2020 | 1888 | 2020 |
| Genetics and epigenetics of NAFLD and NASH: Clinical impact M Eslam, L Valenti, S Romeo Journal of hepatology 68 (2), 268-279, 2018 | 740 | 2018 |
| Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study E Vilar-Gomez, L Calzadilla-Bertot, VWS Wong, M Castellanos, ... Gastroenterology 155 (2), 443-457. e17, 2018 | 532 | 2018 |
| The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease M Eslam, SK Sarin, VWS Wong, JG Fan, T Kawaguchi, SH Ahn, ... Hepatology international 14, 889-919, 2020 | 406 | 2020 |
| Liver diseases in the Asia-Pacific region: a lancet gastroenterology & hepatology commission SK Sarin, M Kumar, M Eslam, J George, M Al Mahtab, SMF Akbar, J Jia, ... The lancet Gastroenterology & hepatology 5 (2), 167-228, 2020 | 330 | 2020 |
| MAFLD identifies patients with significant hepatic fibrosis better than NAFLD S Yamamura, M Eslam, T Kawaguchi, T Tsutsumi, D Nakano, ... Liver International 40 (12), 3018-3030, 2020 | 254 | 2020 |
| The changing epidemiology of liver diseases in the Asia–Pacific region MCS Wong, JLW Huang, J George, J Huang, C Leung, M Eslam, ... Nature reviews Gastroenterology & hepatology 16 (1), 57-73, 2019 | 232 | 2019 |
| Lean NAFLD: a distinct entity shaped by differential metabolic adaptation F Chen, S Esmaili, GB Rogers, E Bugianesi, S Petta, G Marchesini, ... Hepatology 71 (4), 1213-1227, 2020 | 225 | 2020 |
| Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology M Eslam, J George Nature reviews Gastroenterology & hepatology 17 (1), 40-52, 2020 | 196 | 2020 |
| Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores G Targher, A Mantovani, CD Byrne, XB Wang, HD Yan, QF Sun, KH Pan, ... Gut 69 (8), 1545-1547, 2020 | 189 | 2020 |
| ADAPT: an algorithm incorporating PRO‐C3 accurately identifies patients with NAFLD and advanced fibrosis SJ Daniels, DJ Leeming, M Eslam, AM Hashem, MJ Nielsen, A Krag, ... Hepatology 69 (3), 1075-1086, 2019 | 175 | 2019 |
| Patients with diabetes are at higher risk for severe illness from COVID-19 G Targher, A Mantovani, XB Wang, HD Yan, QF Sun, KH Pan, CD Byrne, ... Diabetes & metabolism 46 (4), 335, 2020 | 168 | 2020 |
| Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease M Eslam, AM Hashem, R Leung, M Romero-Gomez, T Berg, GJ Dore, ... Nature communications 6 (1), 6422, 2015 | 165 | 2015 |
| Management of hepatitis C virus genotype 4: recommendations of an international expert panel MA Khattab, P Ferenci, SJ Hadziyannis, M Colombo, MP Manns, ... Journal of hepatology 54 (6), 1250-1262, 2011 | 162 | 2011 |
| Redefining fatty liver disease: an international patient perspective G Shiha, M Korenjak, W Eskridge, T Casanovas, P Velez-Moller, ... The lancet Gastroenterology & hepatology 6 (1), 73-79, 2021 | 134 | 2021 |
| Meta‐analysis: insulin resistance and sustained virological response in hepatitis C M Eslam, R Aparcero, T Kawaguchi, JA Del Campo, M Sata, MA Khattab, ... Alimentary pharmacology & therapeutics 34 (3), 297-305, 2011 | 131 | 2011 |
| International Consensus Panel M Eslam, AJ Sanyal, J George MAFLD: a consensus-driven proposed nomenclature for metabolic associated …, 2020 | 122 | 2020 |
| Pioglitazone improves virological response to peginterferon α‐2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance M Khattab, M Emad, A Abdelaleem, M Eslam, R Atef, Y Shaker, L Hamdy Liver International 30 (3), 447-454, 2010 | 113 | 2010 |
